此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition

2026年5月26日 更新者:Taipei Medical University

Evaluation of the Effects of the PI-YSP-0111 Formulation on Human Gut Microbiota and Body Composition

The expected outcome of this study is that continuous 8-week supplementation with the PI-YSP-0111 prebiotic formulation will exert beneficial effects on gut microbiota modulation and liver health.

研究概览

详细说明

All participants will undergo blood, urine, and fecal sample collection at baseline and after 8 weeks of supplementation. Body composition measurements and questionnaire assessments will be conducted at baseline, after 4 weeks, and after 8 weeks of supplementation. The collected data will be analyzed using a two-way mixed-design analysis of variance (ANOVA) to compare both between-group and within-group differences.

研究类型

介入性

注册 (估计的)

140

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Ming Ta Yang, Professor
  • 电话号码:2275 +886-2-27361661
  • 邮箱:yangrugby@tmu.edu.tw

学习地点

    • Taiwan
      • Taipei、Taiwan、台湾、110
        • 招聘中
        • Taipei Medical University
        • 接触:
      • Taipei、Taiwan、台湾、116
        • 招聘中
        • Taipei Municipal WanFang Hospital(Managed by Taipei Medical University)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  1. Healthy males or females aged 18 to 65 years.
  2. BMI between 23.0 and 40.0 kg/m².
  3. Waist circumference: ≥ 90 cm for males and ≥ 80 cm for females.
  4. Participants are willing to maintain their usual dietary habits, daily routines, and physical activity levels during the study period, and have no plans to relocate.
  5. Participants have fully understood the study procedures and have signed the informed consent form.

Exclusion Criteria:

  1. Presence of gastrointestinal diseases, such as inflammatory bowel disease, irritable bowel syndrome, gastroesophageal reflux disease, Crohn's disease, or a history of bariatric surgery.
  2. Recent history of acute gastroenteritis, constipation or diarrhea; psychiatric disorders (e.g., depression or schizophrenia); cardiovascular diseases (e.g., hypertension); known allergy or hypersensitivity to the investigational product; extreme dietary habits; significant body weight change (>4.5 kg) within the past three months; recent use of antibiotics or antifungal agents; or use of medications affecting gastrointestinal function (such as probiotics, laxatives, or nonsteroidal anti-inflammatory drugs [NSAIDs]).
  3. Exposure to unapproved medications, alcohol abuse, or substance abuse.
  4. Female-specific conditions, including significant gastrointestinal symptoms during menstruation, irregular menstrual cycles, pregnancy, planned pregnancy, or breastfeeding (participants who become pregnant during the study period will also be excluded).
  5. Short-term use of corticosteroids, nonsteroidal anti-inflammatory drugs, immunosuppressive agents, interferons, or immunomodulatory agents within the past one month.
  6. Use of any weight-loss medications (including oral agents, injections, or traditional Chinese medicine) within the past three months.
  7. Participation in any other interventional clinical study within the past one month.
  8. History of cancer or current malignancy within the past two years, except for non-melanoma skin cancer.
  9. Occurrence of major trauma or any surgical procedures within the past one month.
  10. History of diabetic ketoacidosis.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:high-dose intervention group
6 per day(Lactobacillus rhamnosus MB17, Lactobacillus plantarum MB-10, Grape Seed extract, Oligo, Wofberry Extract Powder, Maltose powder, Aerosil, Magnesium Stearate)
实验性的:low-dose intervention group
4 per day(Lactobacillus rhamnosus MB17, Lactobacillus plantarum MB-10, Grape Seed extract, Oligo, Wofberry Extract Powder, Maltose powder, Aerosil, Magnesium Stearate)
安慰剂比较:high-dose placebo group
6 per day(Maltose powder, Aerosil, Magnesium Stearate)
安慰剂比较:low-dose placebo group
4 per day(Maltose powder, Aerosil, Magnesium Stearate)

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Serum Ketone Bodies
大体时间:week0 and week8
week0 and week8
Albumin
大体时间:Week0 and week8
Week0 and week8
Aspartate Aminotransferase (AST)
大体时间:week0 and week8
week0 and week8
Alanine Aminotransferase (ALT)
大体时间:week0 and week8
week0 and week8
Gamma-Glutamyl Transferase (GGT)
大体时间:week0 and week8
week0 and week8
Blood Creatinine
大体时间:week0 and week8
week0 and week8
Blood Urea Nitrogen (BUN)
大体时间:week0 and week8
week0 and week8
Uric Acid
大体时间:week0 and week8
week0 and week8
Sodium (Na⁺)
大体时间:week0 and week8
week0 and week8
Potassium (K⁺)
大体时间:week0 and week8
week0 and week8
Free Fatty Acids (FFA)
大体时间:week0 and week8
week0 and week8
Thyroid Stimulating Hormone (TSH)
大体时间:week0 and week8
week0 and week8
white blood cell (WBC) count/automated differential
大体时间:week0 and week8
week0 and week8
red blood cell (RBC) count
大体时间:week0 and week8
week0 and week8
hemoglobin
大体时间:week0 and week8
week0 and week8
hematocrit
大体时间:week0 and week8
week0 and week8
platelet count
大体时间:week0 and week8
week0 and week8
mean corpuscular volume (M.C.V)
大体时间:week0 and week8
week0 and week8
mean corpuscular hemoglobin concentration (M.C.H.C)
大体时间:week0 and week8
week0 and week8
total cholesterol (TC)
大体时间:week0 and week8
week0 and week8
high-density lipoprotein cholesterol (HDL-C)non-HDL-C
大体时间:week0 and week8
week0 and week8
low-density lipoprotein cholesterol (LDL-C)
大体时间:week0 and week8
week0 and week8
triglycerides (TG)
大体时间:week0 and week8
week0 and week8
glucose AC
大体时间:week0 and week8
week0 and week8
Height
大体时间:week0 , week4 and week8
week0 , week4 and week8
Weight
大体时间:week0 , week4 and week8
week0 , week4 and week8
Body Mass Index (BMI)
大体时间:week0 , week4 and week8
week0 , week4 and week8
Body Composition (muscle mass, fat mass, visceral fat level)
大体时间:week0 , week4 and week8
week0 , week4 and week8
Hip Circumference
大体时间:week0 , week4 and week8
week0 , week4 and week8
Waist-to-Hip Ratio (WHR)
大体时间:week0 , week4 and week8
week0 , week4 and week8
Fecal Sample(Akkermansia muciniphila, qPCR (quantitative polymerase chain reaction))
大体时间:week0, week8
week0, week8
Next-Generation Sequencing (NGS)
大体时间:week0 and week8
week0 and week8
Urinalysis
大体时间:week0 and week8
week0 and week8
Dietary Record
大体时间:week0 , week4 and week8
week0 , week4 and week8
Bowel Movement Record
大体时间:week0 , week4 and week8
week0 , week4 and week8
Gastrointestinal Questionnaire
大体时间:Week0 , week4 and week8
Week0 , week4 and week8

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月8日

初级完成 (估计的)

2027年4月7日

研究完成 (估计的)

2027年4月7日

研究注册日期

首次提交

2026年5月26日

首先提交符合 QC 标准的

2026年5月26日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年6月1日

上次提交的符合 QC 标准的更新

2026年5月26日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • N202603016

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅